Sandi See Tai, MD

Chief development officer at Lexeo.

Articles by Sandi See Tai, MD

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

ByKim G. Johnson, MD, R. Nolan Townsend,Sandi See Tai, MD,Isabella Ciccone, MPH

October 30th 2024

A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

Sandi See Tai, MD

Articles by Sandi See Tai, MD

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology

Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy

Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA

Decision-Making in De-Escalating Therapy for Multiple Sclerosis

Harnessing Genetic Knowledge for Targeted Therapies in Child Neurology: Olivia Kim-McManus, MD